WCG
Wellcare Health Plans Inc.
stock NYSE

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The webinar will feature an in-depth Fireside Chat with RVPH CEO Laxminarayan Bhat, PhD, and KOLs including Dr. Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research) and Dr. Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). The unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia and the phase 3 clinical data of Reviva’s lead drug candidate brilaroxazine for schizophrenia will be discussed. The conversation will be moderated by A.G.P./Alliance Global Partners’ James Molloy.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva will participate in a fireside chat and key opinion leader (KOL) webinar hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The webinar will feature an in-depth Fireside Chat with RVPH CEO Laxminarayan Bhat, PhD, and KOLs including Dr. Larry Ereshefsky, PharmD, BCPP, FCCP (Chief Scientific Officer, Follow the Molecule: CNS Consulting and Clinical Sciences by CenExel Research) and Dr. Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). The unmet medical need and current treatment landscape for patients suffering from symptoms of schizophrenia and the phase 3 clinical data of Reviva’s lead drug candidate brilaroxazine for schizophrenia will be discussed. The conversation will be moderated by A.G.P./Alliance Global Partners’ James Molloy.